Malpractice Insurance and Retatrutide: What Clinic Owners Need to Confirm Before Administering an Investigational Compound

Malpractice insurance is the financial backstop for a physician's clinical practice. Most physicians assume their policy covers everything they do in the course of patient care. For investigational compound administration, that assumption may be wrong — and discovering the gap after a claim has been filed is not a position you want to be in.

Many professional liability (malpractice) policies contain exclusions for research activities. The specific language varies by carrier and policy, but common exclusions include:

• Administration of investigational drugs or devices not approved by the FDA
• Participation in clinical research studies
• Activities conducted outside the scope of standard medical practice
• Administration of compounds obtained through non-standard channels

If your policy contains any of these exclusions, administering retatrutide — an investigational compound with no FDA-approved indication — may not be covered. A patient who experiences a serious adverse event and sues for malpractice could result in a judgment against you that your carrier refuses to pay.

Before you administer the first dose of retatrutide, contact your malpractice carrier and ask the following questions directly:

1. Does my policy cover the administration of investigational compounds? Get the answer in writing. A verbal assurance from a customer service representative is not sufficient.

2. Does my policy cover research activities conducted under an IRB protocol? Some policies that exclude general research activities will cover IRB-approved research. The distinction matters.

3. Does my policy cover claims arising from the administration of compounds obtained through non-standard supply channels? If you are obtaining retatrutide through a research supply network rather than a licensed pharmacy, confirm that your policy covers this.

4. What documentation do I need to maintain to ensure coverage? Some carriers will cover research activities but require specific documentation — IRB approval, informed consent records, adverse event reports — to process a claim. Know what they need before you need it.

5. Do I need a rider or endorsement to cover research activities? Some carriers offer research activity endorsements that extend coverage to IRB-approved research. If your base policy excludes research, this may be the solution.

Many malpractice carriers who would otherwise exclude investigational compound administration will provide coverage for activities conducted under an IRB-approved protocol. The IRB protocol demonstrates that the research was conducted within a recognized regulatory framework, that independent oversight was in place, and that the physician followed established procedures.

This is another reason why the IRB framework is not just a regulatory requirement — it is a practical tool for managing your liability exposure. A carrier who sees an IRB protocol, a signed consent form, and documented adverse event reporting is looking at a very different risk profile than a carrier who sees an undocumented administration of an unapproved compound.

If you are considering leaving your current practice or switching carriers, be aware of tail coverage implications for research activities. Claims arising from retatrutide administration may not surface until months or years after the administration occurred. Ensure that your tail coverage — or your new carrier's prior acts coverage — extends to research activities conducted under your previous policy.

A malpractice judgment in a case involving an investigational compound can be substantial. Plaintiff's attorneys are sophisticated about the regulatory landscape, and a case involving an unapproved compound administered without proper consent or oversight is a compelling narrative for a jury. If your carrier denies coverage because of a research exclusion, you are personally responsible for the judgment.

The cost of confirming your coverage before you start is a phone call and a written confirmation. The cost of discovering a coverage gap after a claim is filed is potentially career-ending.

1. Pull your current malpractice policy and read the exclusions section carefully
2. Contact your carrier's underwriting department (not customer service) with the specific questions above
3. Get written confirmation of coverage — or written confirmation of the exclusion and the endorsement needed to address it
4. If your carrier will not cover IRB-approved research activities, consider whether a different carrier is appropriate for your practice
5. Document this entire process — the inquiry, the response, and any endorsements obtained

This is not a step that can be skipped or deferred. It is a prerequisite for responsible engagement with retatrutide in a clinical setting.